SALEM, N.H., Nov. 1 /PRNewswire/ -- The makers of the WaveSense line of blood glucose monitoring products (AgaMatrix), announced that Mr. Claudio Carboni, formerly of Menarini Diagnostics, has joined as Managing Director to launch WaveSense Europe, its European subsidiary. WaveSense Europe will distribute the company's high accuracy, WaveSense blood glucose meters and test strips in the European market both directly and through local partners.
Carboni has more than 15 years experience in the European blood glucose monitoring (BGM) market and nearly 10 years as Business Unit Director at Menarini Diagnostics. During his tenure, the company grew their BGM business 240% to over euro 160M in annual turnover and to an overall 10% market share in Europe, with leading market positions in Italy and Spain, making the diabetes business unit the largest in the company's diagnostic group. Carboni was also responsible for the business development, product launch, and marketing of Menarini's seven current BGM product lines, including GlucoMen(TM) and GlucoCard(TM). He also introduced the innovative GlucoDay(TM) continuous glucose monitoring system (CGMS). Prior to Menarini, he headed European marketing for MediSense, Inc., which was acquired by Abbott Diabetes Care in 1996.
"With a user base in Europe approaching 200,000, WaveSense has achieved a tremendous amount of presence in key markets such as Germany, Holland, Sweden, and Austria in an extremely short period of time. This is a tribute to how WaveSense's ability to deliver high accuracy resonates with a very discriminating market. I'm delighted to join the team and have a chance to take this to the next level," said Carboni.
The first products to be launched by WaveSense Europe will be the
WaveSense Jazz(TM) and WaveSense Jazz Wireless(TM) products both of which
have high accuracy and no calibration as key features. The features in Jazz
were designed to help users achieve tighter control of their bloo
Copyright©2007 PR Newswire.
All rights reserved